Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To demonstrate that crizotinib (Arm A) is superior to first-line chemotherapy (pemetrexed/cisplatin or pemetrexed/carboplatin) (Arm B), in prolonging PFS in patients with advanced nonsquamous NSCLC whose tumors harbor a translocation or inversion event involving the ALK gene locus.
Critère d'inclusion
- Non small cell lung cancer (NSCLC)